Leading life sciences and IT companies join EndPandemic National Data Consortium
Consortium seeks to speed up the search for a cure by 50%
The EndPandemic National Data Consortium announced it’s received commitments from six leading life sciences and IT companies to join the Consortium. Originally announced on March 30, 2020, the Consortium aims to integrate data from all ongoing and future clinical studies in hopes of dramatically accelerating the analysis of COVID-19 and SARS-CoV-2 research. The group’s ultimate goal is to reduce the time it takes to find a cure to the coronavirus by up to 50%.
The EndPandemic National Data Consortium is working alongside Zaylan Associates and its partner Chrysalis Biomedical Advisors to develop its value proposition, strategic direction, charter and business plan. Meanwhile, a number of organizations have pledged to bring their unique capabilities and expertise to the Consortium to promote clinical-trial data sharing and create a living data repository to generate useful insights for researchers around the world.
"The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health," said Kenneth Massey, Pharm.D., chief life sciences officer of Saama Technologies. "The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate medical experts’ abilities to arrive at actionable decisions in relation to COVID-19 clinical research."
Companies joining the EndPandemic National Data Consortium in its efforts include:
- Andaman7 has built a COVID-19 patient symptom survey with electronic health record and device integration. The platform is HIPAA, GDPR, and 21CFRPart11 compliant and provides access to over 10,000 clinics and hospital EMRs in the U.S.
- Caprion Biosciences, a leading provider of specialized immunology, genomics and proteomics laboratory services, will offer advanced immune monitoring services along with data integration and biostatistical analyses to identify the most optimal treatment combinations and vaccine strategies.
- Clinerion will support research and real-world evidence queries for COVID-19 cases, epidemiology and health economics and outcomes research.
- INDX.AI will adapt its award-winning iCore Platform to help accelerate translational research within silico biomarker discovery for COVID-19 clinical trials.
- Saama Technologies’ AI-powered Life Science Analytics Cloud technology platform will empower researchers around the world to dynamically visualize, analyze, and interrogate data across all available programs.
- Zaylan Associates, in partnership with Chrysalis Biomed Advisors, will continue to develop the group’s strategic direction throughout the pandemic.
The Consortium continues to seek biopharmaceutical companies, clinical research organizations, data analytics leaders and government agencies to join the group in its valiant endeavors. Interested organizations should contact firstname.lastname@example.org or call 1-888-970-3550 to join the Consortium.
Preparing for AI-enabled cyber attacks
MIT technology review insightsDownload now
Cloud storage performance analysis
Storage performance and value of the IONOS cloud Compute EngineDownload now
The Forrester Wave: Top security analytics platforms
The 11 providers that matter most and how they stack upDownload now
Harness data to reinvent your organisation
Build a data strategy for the next wave of cloud innovationDownload now